Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06447870
Status:
RECRUITING
Last Update Posted:
2024-06-07
First Post:
2024-05-19
Brief Title:
Research on the Mechanisms of Treatment Non-response in Inflammatory Bowel Disease Based on Multi-omics Technology
Sponsor:
Nanfang Hospital Southern Medical University
Organization:
Nanfang Hospital Southern Medical University
Study Overview
Official Title:
Research on the Mechanisms of Treatment Non-response in Inflammatory Bowel Disease Based on Multi-omics Technology
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In recent years biologic agents such as infliximab vedolizumab and ustekinumab have demonstrated tremendous potential in the treatment of inflammatory bowel disease IBD altering the traditional treatment paradigm for IBD Despite their significant efficacy there remains a subset of patients who do not respond to biologic agents necessitating research into the response mechanisms of biologic therapy to explore more precise treatment strategies Preliminary work by the principal investigator has identified multiple potential responder cell subtypes to biologic agents which may be influenced by the gut and oral microbiota Therefore this project proposes to investigate the mechanisms of response to biologic agents aiming to explore more precise treatment strategies through the integration of single-cell transcriptomics 16S rRNA and other multi-omics technologies on tissue samples feces saliva peripheral blood etc from IBD patients before and after treatment This will involve integrating bioinformatics analysis and in vitroin vivo functional validation to elucidate the roles of treatment-responsive cell subtypes and gut and oral microbiota in the inflammatory microenvironment of the intestine with the aim of uncovering the mechanisms of biologic agent therapy and providing new clues for the development of next-generation drug targets
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None